Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals.
Fundam Clin Pharmacol. 2011 Dec;25(6):753-61
Authors: Frauger E, Grassi J, Pradel V, Bornet C, Rouby F, Delorme J, Ousset S, Braguer D, Azulay JP, Penot-Ragon C, Harle JR, Bongrand MC, Weiller PJ, Pouget J, Michel G, Micallef J, Reynier JP, Tardieu S, Vanelle P, Blin O,
Since several years, the use of intravenous immunoglobulins (IVIg) has increased. This growth has encouraged some countries to publish guidelines. In parallel, some countries have conducted audits to know how IVIg are used in clinical practice in the light of the available guidelines. The objective of this study was to assess IVIg use in three French university hospitals in 2006. All IVIg administrations were evaluated during 6?months (12 September 2005-12 March 2006) in French university hospitals of Marseille. Different data were recorded for each administration: patient characteristics, indication, formulation and quantity. During the study period, 2802 administrations of IVIg (corresponding to a total quantity of 76?780?g) have been recorded. Four hundred and thirty-five patients received at least one of these administrations. The five most reported indications were multifocal motor neuropathy (11.0% of total quantity), chronic inflammatory demyelinating polyradiculoneuropathy (10.2%), corticoresistant dermatomyositis (10.2%), immune thrombocytopaenia (9.9%) and primary immune deficiency (9.1%). According to available French recommendations, 70% of the IVIg use was for 'acknowledged indications', 9% for 'indications to be assessed' and 18% for 'unwarranted indications'. The 10 most reported indications were 'acknowledged indications' according to available recommendations of the French expert group. Nevertheless, the two most reported indications were not approved by the French Health Products Agency (AFSSAPS) at the time of the study and were approved since.
PMID: 21219439 [PubMed - indexed for MEDLINE]